- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,002 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 74
- States / cities
- Anaheim, California • Covina, California • Greenbrae, California + 68 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 15,654
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cervical Cancer
- Interventions
- Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,023 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 25 more
- Conditions
- Erythema, Radiation Therapy, Secondary Skin Reactions
- Interventions
- VS-200Cr, Standard of care
- Other
- Lead sponsor
- Entrinsic Bioscience Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Fort Myers, Florida
- Conditions
- Skin Aging
- Interventions
- Botulinum toxin type A, Placebo comparator
- Biological
- Lead sponsor
- Revance Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Coral Gables, Florida
- Conditions
- Diabetes, End Stage Renal Disease
- Interventions
- Insulin, Insulin, Asp(B28)-
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Breast Cancer
- Interventions
- ABI-007, Bevacizumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 20
- States / cities
- Melbourne, Florida • Ocoee, Florida • Niles, Illinois + 17 more
- Conditions
- Solid Tumor
- Interventions
- Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil, Irinotecan, Nanoparticle albumin-bound-paclitaxel, Gemcitabine, Docetaxel, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Liposomal Irinotecan
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 26
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 20 more
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, cisplatin, intensity-modulated radiation therapy, Nab-Paclitaxel
- Drug · Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 4
- States / cities
- Cleveland, Ohio • Dallas, Texas • Milwaukee, Wisconsin
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Islets of Langerhans transplantation
- Biological
- Lead sponsor
- CellTrans Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Aging, LONGEVITY 1
- Interventions
- Zepbound
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 55 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Kidney Transplantation, Renal Transplant Recipients
- Interventions
- Lulizumab, Tacrolimus, Thymoglobulin®, Methylprednisolone, Mycophenolate Mofetil, Prednisone
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer
- Interventions
- Bevacizumab, Nivolumab, Rucaparib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Standard Treatment, Incretin-Based Treatment
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
- Interventions
- Odronextamab, Lenalidomide, Rituximab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Plantation, Florida • Indianapolis, Indiana + 5 more
- Conditions
- Lung Cancer
- Interventions
- 18F-FACBC Radiotracer
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Normal Healthy Volunteers
- Interventions
- Fulvestrant, Anastrozole, Placebo, Somatostatin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 55 Years to 80 Years · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- fMRI, Alcohol Drinking, Alcoholism
- Interventions
- Ghrelin, Placebo, fMRI, Alcohol
- Drug · Procedure
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
- Interventions
- Durvalumab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
- Interventions
- Cetuximab, Encorafenib, Nivolumab
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 282
- States / cities
- Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more
- Conditions
- Metastatic Triple Negative Breast Cancer
- Interventions
- L-NMMA, Docetaxel, Amlodipine, Pegfilgrastim, Enteric-coated aspirin
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- End Stage Liver DIsease
- Interventions
- Mobilization with G-CSF and Mozobil
- Drug
- Lead sponsor
- Proteonomix, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Alzheimer Disease, Dementia, Alzheimer's Disease (Incl Subtypes), Aging
- Interventions
- Primary Care Team Advance Care Planning With People with Alzheimer's Disease or a Related Dementia Training, Care as Usual
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Medullary Thyroid Cancer (MTC)
- Interventions
- GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
- Biological
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- insulin detemir, insulin glargine, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 28
- States / cities
- Anaheim, California • Huntington Beach, California • Inglewood, California + 24 more